NEW YORK — DnaNudge said on Wednesday that it has signed a manufacturing agreement with Jabil Healthcare for the cartridges used in its CovidNudge SARS-CoV-2 test.
CovidNudge is a version of DnaNudge's consumer DNA test that has been reengineered for the point-of-care detection of SARS-CoV-2. The RT-PCT-based test involves placing a swab sample into a single-use cartridge for RNA extraction. The RNA is then inserted into a system component called the NudgeBox for reverse transcription to DNA and analysis, with results provided in about an hour.
Under the terms of the deal, Jabil Healthcare — a subsidiary of St. Petersburg, Florida-based Jabil — will make the test cartridges at its Irish manufacturing facility, which is ramping up to produce 1.4 million cartridges a month by early 2021, DnaNudge said.
Additional terms of the agreement were not disclosed.
DnaNudge said that the arrangement will support its commercial delivery program, which includes the fulfillment of a recent order from the UK Department of Health and Social Care for 5.8 million CovidNudge tests.
Last month, London-based DnaNudge said that it had signed a manufacturing agreement for the NudgeBox with Benchmark Electronics.